D69.3: Immune thrombocytopenic purpura
D69.3 is a billable, specific ICD-10-CM code for immune thrombocytopenic purpura. It is valid for submission on a claim.
Check D69.3 with the rest of the claim: free scrubberInclusion terms
Alternative wordings a physician may use in the chart for this same code.
- Hemorrhagic (thrombocytopenic) purpura
- Idiopathic thrombocytopenic purpura
- Tidal platelet dysgenesis
Excludes1 inherited from the categories above D69.3
A category’s note binds every code beneath it.
Written on D69: Purpura and other hemorrhagic conditions
Other codes that can never be billed with D69.3
Their own Excludes1 notes name this code, so the conflict is not listed above.
Risk adjustment
D69.3 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 112 Immune Thrombocytopenia and Specified Coagulation Defects and Hemorrhagic Conditions0.450 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score. Look up the whole chart to see which of its HCCs the hierarchy would zero.
Medicare coverage
D69.3 is named in 16 Medicare coverage policies: 16 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A55639Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions
- A55717Billing and Coding: Lab: Flow Cytometry
- A56380Billing and Coding: Rituximab
- A56416Billing and Coding: Assays for Vitamins and Metabolic Function
Alphabetic index entries that lead here
- Frank's essential thrombocytopenia
- Werlhof's disease
- Dysgenesis›tidal platelet
- Hemorrhage, hemorrhagic›purpura(primary)
- Purpura›hemorrhagic, hemorrhagica
- Purpura›idiopathic(thrombocytopenic)
- Purpura›immune thrombocytopenic
- Thrombocytopenia, thrombocytopenic›essential
- Thrombocytopenia, thrombocytopenic›idiopathic
- Purpura›thrombocytopenic›hemorrhagic
- Purpura›thrombocytopenic›idiopathic
- Purpura›thrombocytopenic›immune
Code history
Unchanged in every release from FY2024 to FY2027.